(Total Views: 791)
Posted On: 11/25/2020 2:27:24 PM
Post# of 148919
Trying To Buy A Vaccine But Just Can't Do It
Effect upon leronlimab?
Half of Americans say they won't get a vaccine.
Vaccine may not help our most vulnerable group, over age 55.
Long term side effects cannot be known for a long time.
Access to the masses will not happen until mid-2021.
The positive results were based upon less than 100 infected volunteers.
The number of uncontrollabe variables in the trials were massive.
The virus globally is presently devastating & not totally recognized as such.
Therapeutics will be vital for a least 2 years.
Phizer/BNTX must be frozen during shipment & FDA postpones meeting until Dec 10th, IMO, because the existing data is not convincing enough. And it may not be as good for older folks, the "higher risk" folks like me. They depended upon symtomatic volunteers calling in vs Phizer contacting them. (Hey, 40,000 people to call???) Thus, infected asymptomatic folks on vaccine, were not considered or even known, which could be many, and they still spread the virus. Volunteers who only got 1 shot of vaccine who became infected, were added to placebo group infected, thus making vaccine look better. BNTX has been volatile, don't trust it.
Moderna is behind time wise, critiques claim there are significant known side effects. It has to ship cold, not frozen. The results are based upon less than 100 infected patients. Stock is up 8% today? It would be approved after Phizer.
I don't trust the initial results.
Astra Zeneca may distribute massive vials of vaccine to third world and south of the equator countries, but it will be cheap and AZN says they plan to make zero profit off the vaccine until the pandemic has ended.
NVAX is up today, eventhough results are not out yet, with 2 competitive vaccines revealing near 95% reduction in infections. Would love to buy some of this but the price is high. Stock price at 100 is down from 184.
Effect upon leronlimab?
Half of Americans say they won't get a vaccine.
Vaccine may not help our most vulnerable group, over age 55.
Long term side effects cannot be known for a long time.
Access to the masses will not happen until mid-2021.
The positive results were based upon less than 100 infected volunteers.
The number of uncontrollabe variables in the trials were massive.
The virus globally is presently devastating & not totally recognized as such.
Therapeutics will be vital for a least 2 years.
Phizer/BNTX must be frozen during shipment & FDA postpones meeting until Dec 10th, IMO, because the existing data is not convincing enough. And it may not be as good for older folks, the "higher risk" folks like me. They depended upon symtomatic volunteers calling in vs Phizer contacting them. (Hey, 40,000 people to call???) Thus, infected asymptomatic folks on vaccine, were not considered or even known, which could be many, and they still spread the virus. Volunteers who only got 1 shot of vaccine who became infected, were added to placebo group infected, thus making vaccine look better. BNTX has been volatile, don't trust it.
Moderna is behind time wise, critiques claim there are significant known side effects. It has to ship cold, not frozen. The results are based upon less than 100 infected patients. Stock is up 8% today? It would be approved after Phizer.
I don't trust the initial results.
Astra Zeneca may distribute massive vials of vaccine to third world and south of the equator countries, but it will be cheap and AZN says they plan to make zero profit off the vaccine until the pandemic has ended.
NVAX is up today, eventhough results are not out yet, with 2 competitive vaccines revealing near 95% reduction in infections. Would love to buy some of this but the price is high. Stock price at 100 is down from 184.
(3)
(0)Scroll down for more posts ▼
